Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04268706 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)
A Phase 2 study of Hodgkin Disease Recurrent and Hodgkin Lymphoma, Adult, sponsored by Tessa Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 97
- Enrollment target
- 5
- Study locations
NCT04268706: Active Phase 2 study of Hodgkin Disease Recurrent and Hodgkin Lymphoma, Adult, sponsored by Tessa Therapeutics.
NCT04268706 is a Phase 2 study of Hodgkin Disease Recurrent and Hodgkin Lymphoma, Adult that is active but no longer recruiting, run by Tessa Therapeutics. The registered enrollment target is 97 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (27% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04268706, a Phase 2 study of Hodgkin Disease Recurrent and Hodgkin Lymphoma, Adult, is active but no longer recruiting, sponsored by Tessa Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 97 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
Primary Outcome
Adverse events
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Bendamustine
- DRUG CD30.CAR-T
Study Locations (5)
California
- City of Hope Comprehensive Cancer Center - Duarte
Illinois
- University of Chicago Medical Center - Chicago
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Tennessee
- Sarah Cannon Research Institute - Nashville
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2037-03 |
| Phase | Phase 2 |
What the registry record for NCT04268706 still lists
NCT04268706 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 97 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (27% lower).
The record links to 4 conditions, with Hodgkin Disease Recurrent appearing as the primary indexed condition, and to 3 interventions - of which Fludarabine is the first listed.
NCT04268706 lists 5 locations in 5 states (California, Illinois, Pennsylvania).
Frequently Asked Questions
What is clinical trial NCT04268706 about?
NCT04268706 is a clinical study titled "Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)". This is a two-part, Phase 2, multicenter, open-label, single arm study to evaluate the safety and efficacy of autologous CD30.CAR-T in adult and pediatric subjects with relapsed or refractory CD30+ classical Hodgkin Lymphoma.
What is the current status of trial NCT04268706?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2021-02-01. Estimated completion is 2037-03.
What conditions does trial NCT04268706 study?
This clinical trial studies the following conditions: Hodgkin Disease Recurrent, Hodgkin Lymphoma, Adult, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric.
What interventions are being tested in trial NCT04268706?
The interventions under investigation include: Fludarabine (DRUG), Bendamustine (DRUG), CD30.CAR-T (DRUG).
Who is sponsoring clinical trial NCT04268706?
This trial is sponsored by Tessa Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04268706 being conducted?
This trial has 5 study locations across California, Illinois, Pennsylvania, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hodgkin Disease Recurrent
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04268706's enrollment target sits among peer trials
97 746th of 2000 higher than 1,254 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03948490 · 97 participants · NA
Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas
- NCT04140487 · 97 participants · Phase 1
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
- NCT04196413 · 97 participants · Phase 1
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
- NCT05223816 · 97 participants · Phase 2
An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI